Health Canada to Review Arcutis Canada’s Submission for Roflumilast Cream 0.15% in AD
Health Canada will review Arcutis Canada, Inc.’s Supplement to a New Drug Submission (SNDS) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. The SNDS includes data from the “INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis” (INTEGUMENT-1 and […]